Eli Lilly and Company (LLY)vsPerrigo Company PLC (PRGO)
LLY
Eli Lilly and Company
$1,372.99
+6.63%
HEALTHCARE · Cap: $1.12T
PRGO
Perrigo Company PLC
$15.92
-0.62%
HEALTHCARE · Cap: $2.30B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1822% more annual revenue ($79.67B vs $4.14B). LLY leads profitability with a 33.5% profit margin vs -41.8%. PRGO appears more attractively valued with a PEG of 1.14. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PRGO
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+74.0%
Fair Value
$56.24
Current Price
$15.92
$40.32 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
Operating margin of 3.8%
Elevated debt levels
Weak financial health signals
ROE of -72.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PRGO
The strongest argument for PRGO centers on Price/Book. PEG of 1.14 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PRGO
The primary concerns for PRGO are Operating Margin, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while PRGO is a turnaround play — different risk/reward profiles.
PRGO carries more volatility with a beta of 0.69 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 47/100), backed by strong 33.5% margins and 47.7% revenue growth. PRGO offers better value entry with a 74.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Perrigo Company PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?